Home-based Exercice Therapy for Patients With Intermittent Claudication Using a New Smartphone Application

NCT ID: NCT05457738

Last Updated: 2025-01-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-19

Study Completion Date

2028-05-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main characteristic of PAD is to limit physical activity by the appearance of claudication of the lower limbs which limits the walking distance, or the maximum distance traveled by the patient before the pain forces to stop. In daily practice, the walking distance is rarely measured at the time of treatment.

Walking rehabilitation is the first-line treatment for these patients (class 1 recommendation from the AHA 2005 and the ESC 2017 with level A evidence). According to the recommendation, a walking session must last at least 30 minutes at the rate of 3 sessions per week for a minimum of 6 months.

Walking rehabilitation should be systematically offered to all claudicating patients, whether operated on or not. It is often sufficient for mild claudication with a walking distance of more than 500 meters. Surgery should be reserved for patients in whom rehabilitation has failed and in whom the claudication is severe (walking distance less than 500 meters). Surgical intervention should not replace rehabilitation, but should be complementary.

Supervised rehabilitation in specialized centers is rarely offered because it is not easily available and involves additional expenses and constraints for the patient (transport, fewer work periods for active patients, etc.). In the absence of specialized center, simple advice is most often given to the patient, who then only has to rely on his personal motivation: this is the so-called "go home and walk".

Therefore, access to well-conducted rehabilitation is a fundamental element of the management of patients with intermittent claudication, which is currently lacking. In the age of digital health, it is necessary to develop innovative tools allowing self-rehabilitation of the patient in addition with remote monitoring by the doctor.

Recent studies have validated and highlighted the interest of using GPS technology for the evaluation of walking activity in claudicants. To date, there are 2 published examples of smartphone applications developed specifically for exercise rehabilitation. The main shortcomings of the solutions proposed in these publications are:

* The need to buy a specific GPS box
* Discomfort for the patient to carry the box either in a backpack or over the shoulder
* The lack of means for the patient to indicate the precise moment when the pain appears
* And consequently the absence of clinical analysis centered on the symptom "walk induced pain" Consumer smartphone applications for GPS activity tracking are not intended for medical use and do not indicate when pain occurs.

In this study, the University Hospital of REIMS will establish a scientific collaboration with the company VascInnove® for the use of a smartphone application, called E-REVA® which offers:

* an assessment of walking activity and claudication parameters (appearance of pain, walking distance, recovery time after pain, total distance travelled, walking speed, etc.)
* help with self-rehabilitation
* quality of life and walking questionnaires

The main innovation is the presence of a button allowing the patient to indicate when the pain appears. The patient will be able to have access via the smartphone application to his statistics and the evolution of his performance over time. The prescribing practitioner will have access, via a secure website, to the statistics of his patient, to whom he will be able to give personalized advice during follow-up consultations.

The aim of this study is to carry out a single-centre prospective randomized stratified study (depending on whether or not patient has been revascularized) in patients with intermittent claudication who will or will not use the rehabilitation assistance smartphone application, seen in consultation for vascular surgery and vascular medicine at the University Hospital of Reims.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intermittent Claudication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients randomized to using the smartphone app

Group Type EXPERIMENTAL

E-REVA® app

Intervention Type OTHER

Use of a smartphone app designed for home-based exercise therapy of patients with intermittent claudication. App's name is E-REVA®.

patients randomized to not using the smartphone app

Group Type ACTIVE_COMPARATOR

No E-REVA® app

Intervention Type OTHER

No use smartphone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

E-REVA® app

Use of a smartphone app designed for home-based exercise therapy of patients with intermittent claudication. App's name is E-REVA®.

Intervention Type OTHER

No E-REVA® app

No use smartphone

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- Patient over 18 years old
* Patient with claudication on PAD for more than 3 months
* IPS (systolic pressure index) less than 0.90 at the level of the diseased limb
* Absence of pathology limiting walk other than PAD
* Patient having benefited from an arterial ultrasound of the lower limbs demonstrating arterial lesion
* Absence of myocardial infarction over the last 6 months
* Absence of cardiac pathology requiring surgery
* Absence of angina
* Patient affiliated or entitled to a social security system
* Patient having given his free and written consent

Exclusion Criteria

* Patient who has not benefited from an arterial ultrasound of the lower limbs
* All contraindications to treadmill events:

* Myocardial infarction within the last 6 months
* angina
* Symptomatic tight aortic valve stenosis
* Pathology limiting walk other than PAD
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CHU de Reims

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Damien JOLLY

Reims, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ambroise DUPREY

Role: CONTACT

03 26 78 46 60 ext. 0033

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ambroise DUPREY

Role: primary

03 26 78 46 60 ext. 0033

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PA22075

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.